Not yet medically reviewed.
Does the RSV Hypertonic Saline 3% offer match the preparation your clinician means? The concentration in the name is not enough to answer that question. The exact current vial and carton labels for product reference B079GR8C6T have not been authenticated here, and a purchase or treatment recommendation remains withheld.
Identify the preparation before discussing treatment
Ask the pharmacist or treating team to identify the exact product, labeled route and intended use. A concentration is only one part of that identification. It does not establish that a product is suitable for a particular person, symptom or device.
The 25-container description associated with this offer is unresolved. No current quantity, sterility, contents or package match is established from it. If you are comparing products, ask for the complete label rather than choosing by the percentage or the RSV wording alone.
No saline mixing, medicine combination, dose, frequency or device-use sequence is given here. References to nasal care, nebulizing or different lung conditions should not be combined into one interchangeable home routine.
Use the RSV care information for the question it answers
CDC advises contacting a healthcare professional for difficulty breathing, insufficient fluids or worsening symptoms in you or your child. This is a reason to seek clinical help, not to wait for a retail product comparison.
The CDC page does not endorse this saline brand or establish a reduction in admissions from buying it. Its public care guidance cannot authenticate an exact preparation or determine an individual’s route of use.
A product carrying RSV in its name should therefore be assessed separately from a diagnosis and care plan. No antiviral, guaranteed recovery or improved-lung-function claim is made for this offer.
Ask what would make the product assessable
FDA’s home-device checklist encourages asking the doctor or supplier questions and taking notes. For any proposed device-and-preparation arrangement, ask the team which exact labels and instructions apply together. A general compatibility statement or familiar device photograph would not answer that.
Breathwell has not tested this preparation’s sterility, operated it with a nebulizer or assessed a patient. No universal-nebulizer compatibility or clinical outcome is established. A current label and a qualified explanation of intended use remain necessary before a responsible product verdict is possible.
Recognize the separate 24-container manufacturer document
Naveh-Pharma’s flyer describes 24 sterile single-use containers of 5mL and calls the product preservative-free. These are attributed manufacturer statements, not a test of a supplied batch. The 24-container document does not resolve the 25-container offer or establish the current contents of B079GR8C6T.
The flyer addresses doctors and refers to an Israeli guideline from December 2011. Its publication date and revision are not established here. That historical professional context is not a current US label, authorization record or individual treatment plan.
No efficacy or dosing text from that flyer is adopted as patient advice. If this is the preparation your team intends, ask them to reconcile the actual vial/carton, route and applicable instructions. Until that match exists, the product recommendation stays open rather than turning a historical marketing claim into a clinical promise.
Archived listing and disclosure
Product reference: B079GR8C6T. No active purchase link or substitute recommendation is provided. No current availability, recall or discontinuation conclusion is made.
Evidence and limits
CDC’s February 20, 2026 public care page and a historical Naveh-Pharma doctor-facing flyer answer different questions. The flyer cites a December 2011 Israeli guideline; its current US applicability and the 24/25-container identity bridge remain unresolved. No clinical approval or firsthand product testing is claimed.
